

Pharmacy Update

December 18th, 2020

Incentive Fee for Narcan/Naloxone for New Mexico Medicaid Plan

Western Sky Community Care

RXBIN: 004336
RXPCN: MCAIDADV
RXGRP: RX5469

Pursuant to the Letter of Direction from the New Mexico Human Services Department, with the Subject: Generic First Policy, Prior Authorization, and Reimbursement for Medication Assisted Treatment (MAT) Medications; Narcan and Naloxone; Title: Medication Assisted Treatment (MAT) Medications; Narcan and Naloxone, your pharmacy will be paid an additional \$37.50 incentive fee on point-of-sale pharmacy transactions for patient education and counseling for nasal Narcan and naloxone kits. This will be in addition to the current drug reimbursement and dispensing fee, on a per claim basis. The additional incentive fee will be paid and is subject to change as directed by the New Mexico Human Services Department.

All other applicable network participation terms and conditions not affected by this notice of change will continue to apply based on the specific network addendum(s) used for each plan, including the reimbursement methodology as outlined in Section 4.3 or Schedule A of the Caremark Provider Agreement, whichever is applicable.

Claims Submission Information

Please use the following fields when submitting Narcan/naloxone products to ensure the patient education and counseling incentive reimbursement:



western sky
community care.

This update applies to:
All Network Pharmacies

State(s):
New Mexico

Line of Business:
Medicaid

Pharmacy Inquiries:
If you have questions, call the Pharmacy Help Desk number provided in the claim response or **1-800-364-6331** if one is not provided.

Payer Sheets:
For additional claim processing information, refer to the CVS Caremark Payer Sheets at www.Caremark.com/pharminfo
> NCPDP Payer Sheets

Pharmacy network participation varies by plan.

The recipient of this fax may make a request to opt-out of receiving telemarketing fax transmissions from CVS Caremark. There are numerous ways you may opt-out: The recipient may call the toll-free number at 877-265-2711 and/or fax the opt-out request to 401-652-0893, at any time, 24 hours a day/7 days a week. The recipient may also send an opt-out request via email to do_not_call@cvscaremark.com. An opt out request is only valid if it (1) identifies the number to which the request relates, and (2) if the person/entity making the request does not, subsequent to the request, provide express invitation or permission to CVS Caremark to send facsimile advertisements to such person/entity at that particular number. CVS Caremark is required by law to honor an opt-out request within thirty days of receipt. An opt out request will not opt you out of purely informational, non-advertisements, Caremark pharmacy communications such as new implementation notices, formulary changes, point-of sale issues, network enrollment forms, and amendments to the Provider Manual.

This communication and any attachments may contain confidential information. If you are not the intended recipient, you are hereby notified that you have received this communication in error and that any review, disclosure, dissemination, distribution, or copying of it or its contents, is prohibited. If you have received this communication in error, please notify the sender immediately by telephone and destroy all copies of this communication and any attachments. This communication is a Caremark Document within the meaning of the Provider Manual.

| Field # | NCPDP Segment & Field Name | Required Vaccine Administration Information for Processing |
|----------------|--|---|
| 439-E4 | DUR/PPS Segment Reason for Service Code | PP (Plan Protocol) |
| 440-E5 | DUR/PPS Segment Professional Service Code Field | PE (Patient Education) |
| 441-E6 | DUR/PPS Segment Result of Service Code | 00 (Not Specified) |
| 438-E3 | Pricing Segment Incentive Amount Submitted Field | ≥ \$0.01 (Submit Incentive Fee) |

Pharmacy network participation varies by plan. Your pharmacy may not be participating in all New Mexico Medicaid plans.

If you need assistance with a current claim, contact the Pharmacy Help Desk.

ATTENTION PHARMACIES/PHARMACISTS IN NEW MEXICO New Mexico needs your help!

New Mexico Department of Health

Opioid Use Disorder (OUD) is a leading cause of death in the USA and New Mexico. Drug overdose is the number one killer of Americans between the ages of 20 and 50. The vast majority of the victims suffer from untreated OUD. Evidence shows that treatment of OUD with buprenorphine profoundly improves survival, improves treatment retention, significantly improves birth outcomes, reduces the use of illicit opioids, decreases transmission of HIV and Hepatitis C, and improves gainful employment. To combat the OUD epidemic, New Mexico increased the number of buprenorphine prescribers and patients being treated with this evidence based and FDA approved medication.